Jerusalem, 10 December, 2025 (TPS-IL) — Israeli biomedical firm Allmed Solutions announced a pioneering success in first-in-human trials, fully replacing a major heart valve via a minimally invasive catheterization procedure, avoiding open-chest surgery. The RoseDoc system, developed with subsidiary TruLeaf Medical, restored tricuspid valve function in two critically ill patients, who were discharged within five days.
The system is geared for patients deemed too high-risk for conventional surgery.
Prof. Oz Shapira, Allmed CEO, called the breakthrough “a defining moment” in cardiac care. The system is now expanding trials to India, South Africa, and Uzbekistan.